Results 11 to 20 of about 136,777 (328)

Quantitative metagenomics reveals unique gut microbiome biomarkers in ankylosing spondylitis

Genome Biology, 2017
Background The assessment and characterization of the gut microbiome has become a focus of research in the area of human autoimmune diseases. Ankylosing spondylitis is an inflammatory autoimmune disease and evidence showed that ankylosing spondylitis may
Chengping Wen, Zhijun Zheng, Tiejuan Shao, Lin Liu, Zhijun Xie, Emmanuelle Le Chatelier, Zhixing He, Wendi Zhong, Yongsheng Fan, Linshuang Zhang, Haichang Li, Chunyan Wu, Changfeng Hu, Qian Xu, Jia Zhou, Shunfeng Cai, Dawei Wang, Yun Huang, Maxime Breban, Nan Qin, Stanislav Dusko Ehrlich   +20 more
doaj   +2 more sources

Neutrophil/lymphocyte and platelet/lymphocyte ratios as potential markers of disease activity in patients with Ankylosing spondylitis: a case-control study

Advances in Rheumatology, 2020
Background The neutrophil/ lymphocyte ratio (NLR) and platelet/lymphocyte ratio (PLR) have the potential to be inflammatory markers that reflect the activity of many inflammatory diseases.
Mohammed Hadi Al-Osami, Nabaa Ihsan Awadh, Khalid Burhan Khalid, Ammar Ihsan Awadh   +3 more
doaj   +2 more sources

Efficacy and safety of upadacitinib for active ankylosing spondylitis refractory to biological therapy: a double-blind, randomised, placebo-controlled phase 3 trial

Annals of the Rheumatic Diseases, 2022
Objectives To evaluate the efficacy and safety of upadacitinib, a Janus kinase inhibitor, in patients with active ankylosing spondylitis (AS) with an inadequate response (IR) to biological disease-modifying antirheumatic drugs (bDMARDs).
D. van der Heijde, X. Baraliakos, J. Sieper, A. Deodhar, R. Inman, H. Kameda, Xiaofeng Zeng, Y. Sui, X. Bu, A. Pangan, P. Wung, I. Song   +11 more
semanticscholar   +1 more source

Long-term Safety of Secukinumab Over Five Years in Patients with Moderate-to-severe Plaque Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis: Update on Integrated Pooled Clinical Trial and Post-marketing Surveillance Data

Acta Dermato-Venereologica, 2022
Secukinumab, a selective interleukin (IL)-17A inhibitor, is approved for use in adult and paediatric psoriasis, psoriatic arthritis, ankylosing spondylitis and non-radiographic axial spondyloarthritis.
A. Gottlieb, A. Deodhar, I. McInnes, X. Baraliakos, K. Reich, S. Schreiber, W. Bao, K. Marfo, H. Richards, L. Pricop, A. Shete, V. Trivedi, Deborah Keefe, C. Papavassilis, P. Jagiello, P. Papanastasiou, P. Mease, M. Lebwohl   +17 more
semanticscholar   +1 more source

Systemic immune‐inflammation index is associated with disease activity in patients with ankylosing spondylitis

Journal of clinical laboratory analysis (Print), 2021
The systemic immune‐inflammation index (SII) is a recently developed indicator for systemic inflammatory response. We aimed to explore the association between SII and disease activity in patients with ankylosing spondylitis (AS).
Junlai Wu, Lifang Yan, K. Chai
semanticscholar   +1 more source

TNF-α-mediated m6A modification of ELMO1 triggers directional migration of mesenchymal stem cell in ankylosing spondylitis

Nature Communications, 2021
Ankylosing spondylitis (AS) is a type of rheumatic disease characterized by chronic inflammation and pathological osteogenesis in the entheses. Previously, we demonstrated that enhanced osteogenic differentiation of MSC from AS patients (AS-MSC) resulted
Zhongyu Xie, Wenhui Yu, Guan Zheng, Jinteng Li, Shuizhong Cen, Guiwen Ye, Zhaofeng Li, Wenjie Liu, Ming Li, Jiajie Lin, Zepeng Su, Yunshu Che, Feng Ye, Peng Wang, Yanfeng Wu, Huiyong Shen   +15 more
semanticscholar   +1 more source

Inflammasome Activation in Ankylosing Spondylitis Is Associated With Gut Dysbiosis

Arthritis & Rheumatology, 2021
We undertook this study to evaluate the activation and functional relevance of inflammasome pathways in ankylosing spondylitis (AS) patients and rodent models and their relationship to dysbiosis.
G. Guggino, D. Mauro, A. Rizzo, R. Alessandro, S. Raimondo, A. Bergot, M. A. Rahman, Jonathan J. Ellis, S. Milling, R. Lories, D. Elewaut, Matthew A Brown, Ranjeny Thomas, F. Ciccia   +13 more
semanticscholar   +1 more source

Increased Risk of Common Orthopedic Surgeries for Patients with Rheumatic Diseases in Taiwan

Medicina, 2022
Background and Objectives: Rheumatic diseases, including rheumatoid arthritis, ankylosing spondylitis, psoriasis, and systemic lupus erythematosus (SLE), are characterized by chronic arthritis or spondyloarthritis, which can lead to joint and spine ...
Min-Chih Hsieh, Malcolm Koo, Chia-Wen Hsu, Ming-Chi Lu   +3 more
doaj   +1 more source

A new and spontaneous animal model for ankylosing spondylitis is found in cynomolgus monkeys

Arthritis Research & Therapy, 2022
Background Ankylosing spondylitis is a progressive, disabling joint disease that affects millions worldwide. Given its unclear etiology, studies of ankylosing spondylitis relied heavily on drug-induced or transgenic rodent models which retain only ...
Huanhuan Jia, Meili Chen, Yanzhen Cai, Xiaoling Luo, Gang Hou, Yongfeng Li, Chunmei Cai, Jun Chen, Qingnan Li, Kai-Kei Miu, Sin-Hang Fung, Zhangting Wang, Ren Huang, Huiyong Shen, Li Lu   +14 more
doaj   +1 more source

Safety and Efficacy of Upadacitinib in Patients With Active Ankylosing Spondylitis and an Inadequate Response to Nonsteroidal Antiinflammatory Drug Therapy: One‐Year Results of a Double‐Blind, Placebo‐Controlled Study and Open‐Label Extension

Arthritis & Rheumatology, 2021
To report the efficacy and safety of upadacitinib through 1 year in patients with ankylosing spondylitis (AS).
A. Deodhar, D. van der Heijde, J. Sieper, F. E. Van den Bosch, W. Maksymowych, Tae-Hwan Kim, M. Kishimoto, A. Ostor, B. Combe, Y. Sui, A. Chu, I. Song   +11 more
semanticscholar   +1 more source